Dr. Kenneth C. Hilty, M.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Cincinnati College of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 759
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Cincinnati College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
NC license 2011-00375 · SC license 30609 -
Internal Medicine Physician
NY license 292417
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Moses H. Cone Memorial Hospital, the Greensboro, NC
- Alamance Regional Medical Center Burlington, NC
Medical groups
- The Moses H Cone Memorial Hospital Operating Corporation (734 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 759
- Services billed
- 1,341
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 246 | 244 |
| Established patient office or other outpatient visit, 30-39 minutes | 213 | 181 |
| Anticoagulant management of patient taking warfarin | 144 | 90 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 142 | 104 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 100 | 93 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 95 | 57 |
| 3d radiographic procedure | 59 | 59 |
| Blood test, clotting time | 56 | 49 |
| Established patient office or other outpatient visit, 20-29 minutes | 47 | 47 |
| Heart muscle strain imaging | 38 | 38 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 33 payments worth $7,410 in total to this clinician.
| Amgen Inc. | $7,126 |
|---|---|
| Novartis Pharmaceuticals Corporation | $59.34 |
| Pfizer Inc. | $53.60 |
| Alnylam Pharmaceuticals Inc. | $51.97 |
| Esperion Therapeutics, Inc. | $28.60 |
| Abiomed | $27.73 |
| Scpharmaceuticals Inc. | $24.62 |
| Bayer HealthCare Pharmaceuticals Inc. | $19.12 |
| Compensation for services other than consulting (speaking, faculty) | $6,534 |
|---|---|
| Food and Beverage | $624 |
| Travel and Lodging | $252 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. May 19, 2025 | Compensation for services other than consulting (speaking, faculty) REPATHA · Cardiovascular | $2,800 |
| Amgen Inc. Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) REPATHA · Cardiovascular | $2,800 |
| Amgen Inc. Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) REPATHA · Cardiovascular | $467 |
| Amgen Inc. May 19, 2025 | Compensation for services other than consulting (speaking, faculty) REPATHA · Cardiovascular | $467 |
| Amgen Inc. Mar 14, 2025 | Travel and Lodging REPATHA · Cardiovascular · travel to SOUTHERN PINES, NC | $129 |
| Amgen Inc. May 19, 2025 | Travel and Lodging REPATHA · Cardiovascular · travel to Pinehurst, NC | $123 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 2 companies. The companies reported $237,475 in research payments for these studies, mostly to the institutions running them.
- A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Amgen Inc. - Study name not reported
Ionis Pharmaceuticals, Inc. - Study name not reported
Ionis Pharmaceuticals, Inc. - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
Amgen Inc. - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Amgen Inc. - Study name not reported
Ionis Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.